Makers Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Reflect Improved Price Attractiveness

The company’s current price-to-earnings (P/E) ratio stands at 35.65, a figure that, while elevated in absolute terms, is now considered attractive relative to its historical valuation and peer group. This marks a shift from previous assessments where the valuation was deemed fair. The price-to-book value (P/BV) ratio at 1.15 further supports this repositioning, indicating that the stock is trading close to its book value, a level often viewed as reasonable for pharmaceutical firms with steady asset bases.

Other valuation multiples reinforce this perspective. The enterprise value to EBITDA (EV/EBITDA) ratio is 5.28, significantly lower than many peers, signalling potential undervaluation. For instance, Bliss GVS Pharma and Kwality Pharma, two notable competitors, trade at EV/EBITDA multiples of 27.23 and 21.9 respectively, underscoring Makers Laboratories’ comparatively attractive pricing.

Peer Comparison Highlights Relative Value

When juxtaposed with its industry peers, Makers Laboratories emerges as a more compelling valuation proposition. Several competitors, including Bliss GVS Pharma, Kwality Pharma, and Shukra Pharma, are classified as very expensive, with P/E ratios ranging from 31.2 to 48.35 and EV/EBITDA multiples well above 20. In contrast, Makers Labs’ EV to capital employed ratio of 1.16 and EV to sales of 0.55 suggest a more conservative market pricing relative to its operational scale.

However, it is important to note that some peers such as Fredun Pharma also share an attractive valuation status, with a P/E of 33.1 and EV/EBITDA of 14.74, indicating that while Makers Laboratories is competitively priced, investors have alternative options within the sector.

Financial Performance and Returns Contextualise Valuation

Makers Laboratories’ return metrics present a mixed picture. Year-to-date, the stock has delivered a robust 20.19% return, outperforming the Sensex which is down 13.36% over the same period. Over three years, the stock has appreciated by 29.98%, again surpassing the Sensex’s 17.90% gain. However, longer-term returns over five years reveal a significant underperformance, with the stock declining 36.48% compared to the Sensex’s 40.70% rise. Over a decade, Makers Laboratories has delivered a strong 113.86% return, though still lagging the Sensex’s 177.19%.

These return patterns suggest episodic volatility and sector-specific challenges, which may explain the cautious Mojo Grade downgrade from Hold to Sell on 1 June 2026, despite the improved valuation parameters.

Quality and Profitability Metrics Remain Moderate

Profitability ratios provide further insight into the company’s fundamentals. The latest return on capital employed (ROCE) is a respectable 15.26%, indicating efficient use of capital relative to earnings before interest and tax. However, the return on equity (ROE) is modest at 3.22%, reflecting limited profitability on shareholder funds. This disparity may temper enthusiasm despite the attractive valuation, as investors weigh quality alongside price.

The PEG ratio is reported as zero, which may indicate either a lack of earnings growth or data unavailability, adding another layer of caution for valuation-based investment decisions.

Price Movement and Market Capitalisation

Currently priced at ₹142.00, Makers Laboratories has seen a slight decline of 0.87% on the day, with intraday highs reaching ₹147.75 and lows at ₹141.85. The stock’s 52-week range spans ₹109.00 to ₹186.70, suggesting it is trading closer to the lower end of its annual price band, which may contribute to the perception of improved price attractiveness.

As a micro-cap entity, Makers Laboratories faces inherent liquidity and volatility risks, which investors should factor into their decision-making process alongside valuation metrics.

Investment Implications and Outlook

The recent shift in valuation grading from fair to attractive for Makers Laboratories Ltd signals a potential entry point for value-oriented investors, especially given the stock’s relative discount to many of its pharmaceutical peers. The subdued EV/EBITDA multiple and P/BV near book value suggest the market may be underpricing the company’s asset base and earnings potential.

Nevertheless, the downgrade in Mojo Grade to Sell and the modest ROE highlight ongoing concerns regarding earnings quality and growth prospects. Investors should carefully balance the improved valuation against these fundamental considerations and the stock’s historical volatility.

Given the mixed return profile relative to the Sensex and sector peers, a cautious approach is warranted. Monitoring upcoming earnings releases and sector developments will be crucial to reassessing the stock’s attractiveness in the near term.

Comparative Valuation Summary

To summarise, Makers Laboratories’ valuation metrics stand as follows: P/E ratio at 35.65, EV/EBITDA at 5.28, and P/BV at 1.15. These compare favourably against peers such as Bliss GVS Pharma (P/E 35.31, EV/EBITDA 27.23), Kwality Pharma (P/E 36.23, EV/EBITDA 21.9), and Shukra Pharma (P/E 48.35, EV/EBITDA 44.12), all rated very expensive. The company’s ROCE of 15.26% is solid, though ROE at 3.22% remains low, reflecting moderate profitability.

Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may find Makers Laboratories’ valuation compelling but should weigh this against the company’s risk profile and recent rating downgrade.

Conclusion

Makers Laboratories Ltd’s transition to an attractive valuation grade amidst a challenging sector backdrop and a Sell Mojo Grade presents a complex investment case. While price multiples suggest undervaluation relative to peers, fundamental profitability and growth concerns persist. This duality underscores the importance of a nuanced, data-driven approach when considering Makers Laboratories for portfolio inclusion.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today